Navigation Links
UT Southwestern scientist receives NIH Director's New Innovator Award
Date:10/1/2007

s behave and how microbes react to those drug concentrations. The aim is to use such information from pharmacokinetics and pharmacodynamics to kill mycobacterium tuberculosis and keep more strains of TB from developing.

Dr. Gumbo said he was thrilled to receive the award.

It will allow me to actually do particular experiments that started with some techniques that I pioneered in the lab using the hollow fiber model of tuberculosis, the native of Zimbabwe said. The typical tuberculosis treatment takes many, many months; usually six months and nine months in some situations. Hopefully, well reduce it to weeks.

Over the five years of the award, Dr. Gumbo will develop a treatment regimen based on blocking the mechanisms that tuberculosis bacteria use to avoid being killed by antibiotics.

Dr. Gumbo, who joined the UT Southwestern faculty in 2006, graduated from the University of Zimbabwe Medical School in Harare, and completed his residency in internal medicine at Case Western Reserve University. He then completed a three-year fellowship to study infectious diseases at the Cleveland Clinic Foundation.

He spent a year doing research at the University of Zimbabwe before accepting a position in 2000 at Albany Medical College and the Ordway Research Institute in Albany, N.Y.

The other winners from Texas were Dr. Pedro Fernandez-Funez of the UT Medical Branch at Galveston and Dr. Kjersti Aagaard-Tillery of Baylor College of Medicine in Houston.


'/>"/>

Contact: Kristen Holland Shear
kristen.hollandshear@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Nobel Prize for Medicine shared by Three scientists
2. Scientists plan human cloning clinic in the United States
3. Scientists crack mechanism of Leptin-Obesity Hormone
4. Scientists use plant hormones to fight cancer
5. American scientists alter gene makeup of babies
6. Expose on eating disorders!! Scientists trace “brain’s eating control center pathway”
7. Scientists found ancient Human Germ Killer
8. Scientists locate key hormone involved in appetite control
9. Scientists open the book of life
10. Electronic nose by Italian scientists
11. Scientists review SARS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2008)... WASHINGTON, Aug. 29 /PRNewswire-USNewswire/ -- Th...onsistent procedures to allow the public to,see ex...ished today in the,Federal Register http://edocke...will ensure that the best and latest available evi... risk assessments for health,standards regulating ...
(Date:8/29/2008)...iation may have caused chromosomal change that rai... FRIDAY, Aug. 29 (HealthDay News) -- Some Japanese...in Hiroshima and Nagasaki experienced key genetic ...of thyroid cancer, new research indicates. , Pa...o a particular genetic mutation involving the so-c...
(Date:8/29/2008)... LEEDS, England, August 29 /PRNewswire/ --, - MYA...ce for Recent,Big Brother Stars but the big Questi...as, mirrors all around and being on national,telev...ct on how you feel,about the way you look. For man... a reality. Upon leaving the house contestants may...
(Date:8/29/2008)... Dr. Milton Owens and the Co... Southern California to provide protection for cas...on, and the Hispanic community is benefiting. , ...ust 29, 2008 -- Dr. Milton Owens and the Coastal C...rn California to provide protection for cash payin...
Breaking Medicine News(10 mins):Health News:Notice of Proposed Rulemaking on U.S. Department of Labor's Risk Assessment Procedures Published in Federal Register 2Health News:Some Hiroshima Survivors at Thyroid Cancer Risk 2Health News:Some Hiroshima Survivors at Thyroid Cancer Risk 3Health News:MYA Makes Big Brother Stars Amazing! 2Health News:MYA Makes Big Brother Stars Amazing! 3Health News:Coastal Center for Obesity Offers Hispanics Weight Loss Surgery with a Warranty 2
...ccording to a recent study, are increasingly turni...ease. In this context physicians need to be aware...de the patients to the most reliable, accurate and...niversity of Pennsylvania Cancer Center in Philade...
...ems to be the latest mantra of Pfizer. The pharma...ree antifungal drug to 50 countries hardest hit by...close on the heels of the South African Government...ompanies. In an announcement on Wednesday Pfizer ...
...ich are protective substances, produced by the bod...em kill the TB bacteria, researchers in the UK rep...he journal Nature Medicine, these heat-shock prote...ody help cells survive stressful times and bolster...
...rket in India is expected to grow into a three bil...ndia finance report. The big leap is expected to ...one billion dollars. Biogenerics, biopharmaceutic...tors are all poised for the big leap, both nationa...
Other Medicine News:
(Date:8/26/2008)...stCall/ -- XTENT, Inc.,(Nasdaq: XTNT ) today anno...om the CUSTOM II trial was published in the most r...rvention. The lead author of the article was,Dr. P...r Utrecht, Utrecht,The Netherlands on behalf of t...across Europe., The one-year CUSTOM II trial, a s...
(Date:8/25/2008).../ -- Joseph F. Finn, Jr.,C.P.A. ("Finn"), Assigne...,the benefit of creditors, announced today that al...d at a sealed bid auction on October 10,2008., S...opa-Carbidopa that,is the current gold standard tr... estimated at approximately $250 million. Signific...
(Date:8/22/2008)..., - Dangerous Bacteria Infect Three Million Peopl...tried can also be innovative: already in,Ancient G...ial. This,ability is now playing an important role... In a worldwide noted field test, a whole hospital...rg, Germany, was equipped with,door handles, door ...
(Date:8/21/2008)...tial in independent study of ad...g. 21 /- A recently published article...ation has expanded our,understanding of the clinic...in adult patients at risk for organ rejection or i...ablo Sanchez-Velasco and his colleagues in the Can...
Breaking Medicine Technology:XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 2XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 4Spherics, Inc. Offers Extended Release Formulation for Sustained and Stable Levodopa Levels 2Copper Eliminates Resistant Hospital Germs in a Worldwide Field Test 2Copper Eliminates Resistant Hospital Germs in a Worldwide Field Test 3New Data Support Role for Monitoring of Cell-Mediated Immunity in Adult Patients Following Renal Transplantation 2New Data Support Role for Monitoring of Cell-Mediated Immunity in Adult Patients Following Renal Transplantation 3Commonwealth Fund Commission issues reform recommendations for next president 6383 1Commonwealth Fund Commission issues reform recommendations for next president 6383 2Commonwealth Fund Commission issues reform recommendations for next president 6383 3FDA Hears Pros Cons of Pharmacist to Patient Drug Sales 6381 1FDA Hears Pros Cons of Pharmacist to Patient Drug Sales 6381 2FDA Hears Pros Cons of Pharmacist to Patient Drug Sales 6381 3FDA Hears Pros Cons of Pharmacist to Patient Drug Sales 6381 4BIO key Reports Third Quarter 2007 Results 1228 1BIO key Reports Third Quarter 2007 Results 1228 2BIO key Reports Third Quarter 2007 Results 1228 3BIO key Reports Third Quarter 2007 Results 1228 4BIO key Reports Third Quarter 2007 Results 1228 5Predicting the future in ovarian cancer 6379 1Predicting the future in ovarian cancer 6379 2
...USINESS WIRE)--Jun 7, 2007 - Clinical results from...the American,Headache Society (AHS) annual meeting...itonin gene-related peptide (CGRP),receptor antago...two hours after dosing compared to placebo, and th...as generally well tolerated in,the study. Response...
... 900-mcg dosed every two weeks achieved an SVR rat...(ITT analysis), with,more favorable quality-of-lif...ire-FirstCall/ -- Human,Genome Sciences, Inc. toda...2b clinical trial of Albuferon(R) (albinterferon a...-naive patients with,genotype 1 chronic hepatitis ...
Other Medicine Technology:Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 2Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 3Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 4Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 5Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 2Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 3Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 4Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 5Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 6Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 7Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 8
...ssional Diagnostics is a leading provider of immun...A test menu that includes kits for autoimmune dise...ellaneous conjugates and components. Our Impact IF...rates and kit sizes to choose from. Kit components...
...ssional Diagnostics is a leading provider of immun...A test menu that includes kits for autoimmune dise...ellaneous conjugates and components. Our Impact IF...rates and kit sizes to choose from. Kit components...
...us disease ELISA products make us a leader in this...ntegration into the busy laboratory, our Infectiou...lity and run-to-run consistency. Our Infectious Di...s for a wide range of serological assays including...
...us disease ELISA products make us a leader in this...ntegration into the busy laboratory, our Infectiou...lity and run-to-run consistency. Our Infectious Di...s for a wide range of serological assays including...
Medicine Products: